Myasthenia Gravis – Epidemiology Forecast to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Myasthenia gravis (MG) is the most common neuromuscular junction disorder, and is characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles (Lai and Tseng, 2010). In this disease, receptors for acetylcholine at the neuromuscular junction are blocked, altered, or destroyed by the antibodies (immune proteins), which prevent the muscle from contracting. In some cases, antibodies to other proteins, such as the muscle-specific receptor tyrosine kinase (MuSK) protein, can also lead to impaired transmission at the neuromuscular junction (National Institute of Neurological Disorders and Stroke, 2017).

GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and population-based studies to build the forecast for the diagnosed prevalent cases of MG in the 7MM. GlobalData epidemiologists applied the prevalence of MG drawn from the above source to each country’s population to calculate the number of estimated diagnosed prevalent cases for severity according to MGFA classifications respectively.

The following data describes the epidemiology of MG. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of MG in the 7MM from 152,798 diagnosed prevalent cases in 2018 to 169,077 diagnosed prevalent cases in 2028, with an Annual Growth Rate (AGR) of 1.07% during the forecast period. In 2018, the US had the highest number of diagnosed prevalent cases of MG in the 7MM with 52,742 cases; whereas the UK had the fewest number of diagnosed prevalent cases with 11,637 cases.

Scope

The Myasthenia Gravis Epidemiology Report and Model provide an overview of the risk factors and global trends of Myasthenia Gravis (MG) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of MG segmented by age, sex, and severity according to Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V) in the 7MM. Additionally, the model includes a 10-year epidemiological forecast for the antibody status of MG.

The MG epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The MG Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global MG market.

Quantify patient populations in the global MG market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MG therapeutics in each of the markets covered.

Understand magnitude of MG population by its severity.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Myasthenia Gravis: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of MG

3.4.4 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of MG by Severity

3.5 Epidemiological Forecast for MG (2018–2028)

3.5.1 Diagnosed Prevalent Cases of MG

3.5.2 Age-Specific Diagnosed Prevalent Cases of MG

3.5.3 Sex-Specific Diagnosed Prevalent Cases of MG

3.5.4 Diagnosed Prevalent Cases of MG by Severity

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologists

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Risk Factors and Comorbidities for MG

Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018 and 2028

Figure 2: 7MM, Diagnosed Prevalence of MG, %, Both Sexes, All Ages, 2018

Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MG

Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MG by Severity

Figure 5: 7MM, Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018

Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018

Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of MG, N, All Ages, 2018

Figure 8: 7MM, Diagnosed Prevalent Cases of MG by Severity, N, Both Sexes, All Ages, 2018

Frequently asked questions

Myasthenia Gravis – Epidemiology Forecast to 2028 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Myasthenia Gravis – Epidemiology Forecast to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myasthenia Gravis – Epidemiology Forecast to 2028 in real time.

  • Access a live Myasthenia Gravis – Epidemiology Forecast to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.